Literature DB >> 7952575

Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease.

M Di Francia1, D Barbier, J L Mege, J Orehek.   

Abstract

Unexplained weight loss is common in chronic obstructive pulmonary disease (COPD). Blood levels of tumor necrosis factor-alpha (TNF-alpha), a cytokine causing cachexia in laboratory animals, are elevated in various human diseases associated with weight loss. We therefore prospectively measured TNF-alpha serum levels (immunoradiometric assay) in patients with clinically stable COPD (n = 30; all male; mean age, 65 yr) whose weight was less (Group I; n = 16) or more (Group II; n = 14) than the lower limit of normal taken from Metropolitan Life Insurance Company tables. The patients had no cause known to elevate TNF-alpha serum levels; notably, they were not infected. Group I patients had unintentionally lost weight during the previous year, whereas the weight of Group II patients had not changed during the same period. The two groups had similar chronic airflow obstruction and arterial blood gas impairment; hyperinflation and reduction in diffusing capacity were more pronounced in Group I, but differences were not significant. TNF-alpha serum levels (pg/ml; mean [SD]) were significantly higher in Group I than in Group II (70.2 [100.0] versus 6.7 [6.4]; p < 0.001). Group II TNF-alpha serum levels did not differ significantly from those of healthy subjects (7.8 [3.9]), whereas those of Group I were significantly higher (p < 0.001). Because renal function was in the normal range, we conclude that increased TNF-alpha production--and not decreased TNF-alpha clearance--is a likely cause of weight loss in patients with COPD.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7952575     DOI: 10.1164/ajrccm.150.5.7952575

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  82 in total

Review 1.  Models of accelerated sarcopenia: critical pieces for solving the puzzle of age-related muscle atrophy.

Authors:  Thomas W Buford; Stephen D Anton; Andrew R Judge; Emanuele Marzetti; Stephanie E Wohlgemuth; Christy S Carter; Christiaan Leeuwenburgh; Marco Pahor; Todd M Manini
Journal:  Ageing Res Rev       Date:  2010-05-14       Impact factor: 10.895

Review 2.  [Comorbidities of COPD].

Authors:  H Watz; H Magnussen
Journal:  Internist (Berl)       Date:  2006-09       Impact factor: 0.743

3.  Systemic inflammation and progression of COPD.

Authors:  Jørgen Vestbo
Journal:  Thorax       Date:  2007-06       Impact factor: 9.139

4.  Association of tumor necrosis factor-alpha-863C/A gene polymorphism with chronic obstructive pulmonary disease.

Authors:  Yung-Che Chen; Shih-Feng Liu; Chien-Hung Chin; Chao-Chien Wu; Chung-Jen Chen; Hsueh-Wen Chang; Yi-Hsi Wang; Yu-Hsiu Chung; Tung-Ying Chao; Meng-Chih Lin
Journal:  Lung       Date:  2010-03-30       Impact factor: 2.584

5.  COPD is not COPD is not allergy.

Authors:  Stanislav Suskovic
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

6.  Therapeutic Treatment with Abdominal Adipose Mesenchymal Cells Does Not Prevent Elastase-Induced Emphysema in Rats.

Authors:  Pınar Yıldız Gülhan; Mehmet Savaş Ekici; Mehmet Niyaz; Muhammet Gülhan; Mustafa Emre Erçin; Aydanur Ekici; Nurkan Aksoy
Journal:  Turk Thorac J       Date:  2020-01-01

7.  Biomarkers of systemic inflammation in stable and exacerbation phases of COPD.

Authors:  Fisun Karadag; Aslihan B Karul; Orhan Cildag; Mustafa Yilmaz; Hatice Ozcan
Journal:  Lung       Date:  2008-09-20       Impact factor: 2.584

8.  Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.

Authors:  Nicola J Sinden; Robert A Stockley
Journal:  Ther Adv Chronic Dis       Date:  2010-03       Impact factor: 5.091

Review 9.  Nutritional aspects of chronic obstructive pulmonary disease.

Authors:  Daniel A King; Francis Cordova; Steven M Scharf
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

10.  Glutathione depletion impairs myogenic differentiation of murine skeletal muscle C2C12 cells through sustained NF-kappaB activation.

Authors:  Esther Ardite; Joan Albert Barbera; Josep Roca; Jose C Fernández-Checa
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.